Pneumococcal Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

Global Pneumococcal Vaccine Market was valued at USD 9.63 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.26% through 2030. The global pneumococcal vaccine market is a crucial segment of the pharmaceutical and healthcare industry, primarily aimed at preventing infections caused by Streptococcus pneumoniae bacteria. Pneumococcal infections can lead to various illnesses, including pneumonia, meningitis, and sepsis, and they pose a significant public health threat, particularly to young children and the elderly.

For instance, according to WHO estimates in 2023, pneumococcal infections cause approximately 1.6 million deaths worldwide each year, with nearly one million fatalities occurring in children under the age of five. Given its significant impact on child mortality, WHO classifies pneumococcal disease as a high-priority condition for vaccination. To combat this, the organization strongly recommends the use of 13-valent pneumococcal conjugate vaccines (PCVs) as an effective preventive measure. These vaccines play a crucial role in reducing severe infections such as pneumonia, meningitis, and sepsis in young children, particularly in regions with limited healthcare access and high disease prevalence.

Key Market Drivers

Rising Global Awareness of Pneumococcal Diseases

One of the fundamental reasons behind the growth of the pneumococcal vaccine market is the increasing understanding of the serious health consequences posed by pneumococcal diseases. Medical professionals, policymakers, and the general public are becoming more aware of the debilitating and potentially fatal nature of these infections, leading to a heightened sense of urgency in preventing them. For instance, in June 2023, Sanofi and SK bioscience announced positive results from phase II clinical trials of their 21-valent conjugate vaccine candidate. The findings suggest that GBP410 may provide broader serotype coverage compared to existing vaccines, potentially expanding its market share. Based on these promising results, the companies plan to advance to phase III trials in 2024, with the goal of obtaining final data by 2027.

Public health organizations and advocacy groups have played a pivotal role in disseminating information about pneumococcal diseases. Their efforts include educational campaigns, public service announcements, and initiatives that emphasize the importance of vaccination. As individuals become better informed, they are more likely to seek out and request pneumococcal vaccines.

Key Market Challenges

Economic Disparities

One of the most prominent challenges is the economic disparity among nations. High-income countries often have better access to pneumococcal vaccines due to robust healthcare infrastructures and funding. In contrast, low- and middle-income countries struggle to afford these vaccines, leading to unequal access and health disparities.

Key Market Trends

Next-Generation Vaccines

Advancements in vaccine technology are paving the way for next-generation pneumococcal vaccines. These vaccines are designed to offer broader protection against a wider range of pneumococcal serotypes. By harnessing innovative formulations and targeting evolving bacterial strains, next-gen vaccines are poised to enhance vaccine effectiveness and durability.

Key Market Players

• GSK PLC
• Pfizer Inc
• Merck KGaA
• Serum Institute of India Pvt Ltd
• CSL Ltd
• Sanofi SA
• Walvax Biotechnology Co., Ltd
• Beijing Minhai Biotechnology Limited Company
• AstraZeneca PLC
• BioNTech

Report Scope:

In this report, the Global Pneumococcal Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pneumococcal Vaccine Market, By Type:

• Conjugate Vaccines
• Polysaccharide Vaccines

Pneumococcal Vaccine Market, By Indication:

• Bronchitis
• Meningitis
• Pneumonia
• Sepsis

Pneumococcal Vaccine Market, By Product:

• Pneumovax23
• Prevnar 13
• Synflorix

Pneumococcal Vaccine Market, By Distribution:

• Government Authorities
• Non-Governmental Organizations

Pneumococcal Vaccine Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pneumococcal Vaccine Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.